Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.44 |
| ▸ | WNT3A | P56704 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703417 | 0.85 | KDM4E (0.53) | CYP19A1SMN1; SMN2CYP1A2CYP2C19KDM4E | |
| SCHEMBL17985011 | 0.83 | KDM4E (0.60) | CYP19A1SMN1; SMN2CYP1A2CYP2C19HSP90AA1 | |
| SCHEMBL3703151 | 0.83 | RAB9A (0.49) | SMN1; SMN2CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL933781 | 0.83 | KDM4E (0.51) | SMN1; SMN2CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL7085670 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP1A2CYP2C19HRH1CTNNB1 | |
| Iodide SCHEMBL6263376 | 0.82 | KDM4E (0.59) | CYP19A1SMN1; SMN2CYP1A2CYP2C19HSP90AA1 | |
| SCHEMBL933753 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL787766 | 0.81 | MAPT (0.61) | SMN1; SMN2CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL3702884 | 0.81 | KDM4E (0.44) | CYP19A1SMN1; SMN2CYP1A2CYP2C19KDM4E | |
| SCHEMBL30134679 | 0.81 | MAPT (0.61) | SMN1; SMN2CYP1A2CYP2C19KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2259689-B1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2011-11-16 | — | — | EP | disclosed |
| EP-2259689-B1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| WO-2009105906-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272656-A1 | Flavor Molecules | TAS2R30, TAS2R31, TAS2R1 | CYP19A1 3585/4885SMN1; SMN2 1125/4885CYP1A2 2674/4885 |
| US-20100040753-A1 | FLAVOR MOLECULES | TAS2R30, TAS2R31, TAS2R1 | CYP19A1 3585/4885SMN1; SMN2 1125/4885CYP1A2 2674/4885 |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | CYP19A1 2441/4885SMN1; SMN2 2361/4885CYP1A2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.